Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
Richard A. Larson, Sumithra J. Mandrekar, Lucas J. Huebner, Ben L. Sanford, Kristina Laumann, Susan M. Geyer, Clara D. Bloomfield, Christian Thiede, Thomas W. Prior, Konstanze Döhner, Guido Marcucci, Maria Teresa Voso, Rebecca B. Klisovic, Ilene Galinsky, Andrew H. Wei, Jorge Sierra, Miguel Á. Sanz, Joseph Brandwein, Théo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Jürgen Krauter, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Hartmut Döhner, Richard M. Stone
Topics & Concepts
MidostaurinMedicineInternal medicineCytarabineOncologyCumulative incidenceMyeloid leukemiaPreleukemiaMaintenance therapyTransplantationSurgeryLeukemiaChemotherapyAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchHistone Deacetylase Inhibitors Research